s why even a single case has to be taken seriously. A
safety signal from any study - and not just
safety data from short term efficacy and
safety studies (used for labeling) - needs to be evaluated. This means data from long term safety studies needs to be evaluated as well as the data from even longer, ongoing safety studies and from clinical pharmacology studies. Some of this information also needs to be examined during development of a drug.